

Financial Tear Sheet

Primary IR Contact

Ed Bell
T +1 206-272-4345
invest@ctibiopharma.com
(mailto:invest@ctibiopharma.com)

Transfer Agent

Computershare

Mail:
Computershare Investor Services
P.O. Box 43078
Providence, RI 02940-3078

Overnight Delivery:
Computershare Investor Services
250 Royall Street
Canton, MA 02021
United States of America

T: 312-588-4187
F: 312-601-4332
www.Computershare.com
(http://www.computershare.com)

Corporate Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited.

Stock Performance: CTIC (Nasdaq)

Exchange NASDAQ CM (US Dollar)

Price **\$1.91**

Change (%) ▼ 0.04 (2.05%)

Volume 302,662

52 Week Low \$1.86

Market Cap \$113,078,402

Rolling EPS -0.89

PE Ratio 0

Shares Outstanding 57,988,924

Data as of 08/15/18 4:00 p.m. ET



Recent Headlines & Events

Aug 02, 2018 - 8:00 a.m.

CTI BioPharma Reports Second Quarter
2018 Financial Results
([phoenix.zhtml?c=92775&p=irol-
newsArticle&ID=2361698](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2361698))

There are currently no events scheduled.

Jul 26, 2018 - 4:01 p.m.

CTI BioPharma to Report Second Quarter
2018 Financial Results on August 2, 2018
([phoenix.zhtml?c=92775&p=irol-
newsArticle&ID=2360352](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2360352))

Jul 18, 2018 - 7:00 a.m.

CTI BioPharma Announces Pacritinib
Program Update Following Type B Meeting
with U.S. FDA ([phoenix.zhtml?c=92775&
p=irol-newsArticle&ID=2358781](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2358781))

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	117	210.28	73.6	42,670,361
Mutual Fund	93	48.04	18.6	10,796,714
Insider *	7	1.64	0.7	412,905

**Insider values reflect direct beneficial ownership.*

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
BVF Partners L.P.	6,929,690	12.0	0	06/30/18
OrbiMed Advisors, LLC	5,000,000	8.6	0	06/30/18
Stonepine Capital Management, LLC	4,049,298	7.0	-1,092,448	06/30/18
New Enterprise Associates (NEA)	3,750,000	6.5	0	06/30/18
Franklin Advisers, Inc.	3,472,300	6.0	0	06/30/18
BlackRock Institutional Trust Company, N.A.	2,564,039	4.4	2,138,492	06/30/18
The Vanguard Group, Inc.	2,388,851	4.1	235,987	06/30/18
Great Point Partners, LLC	1,537,020	2.7	-150,000	06/30/18
Fidelity Management & Research Company	1,400,000	2.4	0	06/30/18
NB Public Equity Komplementar ApS	1,356,635	2.3	90,000	12/31/16

Data provided by Nasdaq. Minimum 15 minutes delayed.